More Resources Sought For Using Patient-Preference Data In US Device Reviews
This article was originally published in SRA
The US Food and Drug Administration's vision for the next Medical Device User Fee Act is to ensure the reliability and sustainability of the device review program, but it is also considering 'other components' not traditionally considered, such as how to get resources to include patient preferences in decision-making, the agency said in minutes of a recent MDUFA IV patient/consumer stakeholder meeting1.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.